p27kip1: A New Multiple Endocrine Neoplasia Gene?

被引:46
作者
Marinoni, Ilaria [1 ]
Pellegata, Natalia S. [1 ]
机构
[1] Helmholtz Zentrum Munchen, Inst Pathol, DE-85764 Neuherberg, Germany
关键词
Multiple endocrine neoplasia; p27kip1; Cell cycle regulation; KINASE INHIBITOR P27; P27(KIP1) MESSENGER-RNA; GERM-LINE MUTATIONS; CDK INHIBITORS; CELL-MIGRATION; BREAST-CANCER; PITUITARY-ADENOMAS; TUMOR SUPPRESSION; PROSTATE-CANCER; EXPRESSION;
D O I
10.1159/000320366
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple endocrine neoplasias (MEN) are autosomal dominant disorders characterized by the occurrence of tumors in at least two endocrine glands. Two types of MEN syndromes have long been known: MEN type 1 (MEN1) and MEN type 2 (MEN2), associated with a different spectrum of affected organs. MEN1 and MEN2 are caused by germline mutations in the MEN1 tumor suppressor gene and the RET proto-oncogene, respectively. Lately, a new type of MEN was identified (named MEN4) which is due to mutations in the CDKN1B gene, encoding for p27kip1 (p27), a cyclin-dependent kinase (Cdk) inhibitor that regulates the transition of cells from G1 to S phase. p27 is a non-canonical tumor suppressor since it is usually not somatically mutated in human cancers but it is often downregulated by post-translational mechanisms. The discovery of MEN4 has defined a new role for CDKN1B as a tumor susceptibility gene for multiple endocrine tumors. To date, six germline CDKN1B mutations have been found in patients with a MEN1-like phenotype but negative for MEN1 mutations. Due to the limited number of patients so far identified, the phenotypic features of MEN4 are not clearly defined. Here, we review the clinical and molecular characteristics of the MEN4 syndrome and summarize the main functions of p27 to better comprehend how their alteration can predispose to neuroendocrine tumors. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:19 / 28
页数:10
相关论文
共 74 条
[1]   Rare Germline Mutations in Cyclin-Dependent Kinase Inhibitor Genes in Multiple Endocrine Neoplasia Type 1 and Related States [J].
Agarwal, Sunita K. ;
Mateo, Carmen M. ;
Marx, Stephen J. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (05) :1826-1834
[2]   Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas [J].
Bamberger, CM ;
Fehn, M ;
Bamberger, AM ;
Lüdecke, DK ;
Beil, FU ;
Saeger, W ;
Schulte, HM .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 140 (03) :250-255
[3]   p27Kip1 modulates cell migration through the regulation of RhoA activation [J].
Besson, A ;
Gurian-West, M ;
Schmidt, A ;
Hall, A ;
Roberts, JM .
GENES & DEVELOPMENT, 2004, 18 (08) :862-876
[4]   Regulation of the cytoskeleton: An oncogenic function for CDK inhibitors? [J].
Besson, A ;
Assoian, RK ;
Roberts, JM .
NATURE REVIEWS CANCER, 2004, 4 (12) :948-955
[5]   Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype [J].
Besson, Arnaud ;
Hwang, Harry C. ;
Cicero, Samantha ;
Donovan, Stacy L. ;
Gurian-West, Mark ;
Johnson, Dianna ;
Clurman, Bruce E. ;
Dyer, Michael A. ;
Roberts, James M. .
GENES & DEVELOPMENT, 2007, 21 (14) :1731-1746
[6]   Distinct Developmental Roles of Cell Cycle Inhibitors p57Kip2 and p27Kip1 Distinguish Pituitary Progenitor Cell Cycle Exit from Cell Cycle Reentry of Differentiated Cells [J].
Bilodeau, Steve ;
Roussel-Gervais, Audrey ;
Drouin, Jacques .
MOLECULAR AND CELLULAR BIOLOGY, 2009, 29 (07) :1895-1908
[7]   Guidelines for diagnosis and therapy of MEN type 1 and type 2 [J].
Brandi, ML ;
Gagel, RF ;
Angeli, A ;
Bilezikian, JP ;
Beck-Peccoz, P ;
Bordi, C ;
Conte-Devolx, B ;
Falchetti, A ;
Gheri, RG ;
Libroia, A ;
Lips, CJM ;
Lombardi, G ;
Mannelli, M ;
Pacini, F ;
Pondder, BAJ ;
Raue, F ;
Skogseid, B ;
Tamburrano, G ;
Thakker, RV ;
Thompson, NW ;
Tomassetti, P ;
Tonelli, F ;
Wells, SA ;
Marx, SJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) :5658-5671
[8]   Reduced p18INK4c, p21CIP1/WAF1 and p27KIP1 mRNA levels in tumours of primary and secondary hyperparathyroidism [J].
Buchwald, PC ;
Åkerstrom, G ;
Westin, G .
CLINICAL ENDOCRINOLOGY, 2004, 60 (03) :389-393
[9]   p27: A potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior [J].
Canavese, G ;
Azzoni, C ;
Pizzi, S ;
Corleto, VD ;
Pasquali, C ;
Davoli, C ;
Crafa, P ;
Delle Fave, G ;
Bordi, C .
HUMAN PATHOLOGY, 2001, 32 (10) :1094-1101
[10]   SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 [J].
Carrano, AC ;
Eytan, E ;
Hershko, A ;
Pagano, M .
NATURE CELL BIOLOGY, 1999, 1 (04) :193-199